Hydroxychloroquine

Active ingredient: Hydroxychloroquine Sulfate

In short: Hydroxychloroquine sulfate tablets are indicated in adult and pediatric patients for the: Treatment of uncomplicated malaria due to Plasmodium falciparum, Plasmodium malariae, Plasmodium vivax,and Plasmodium ovale. Prophylaxis of malaria in geographic areas where chloroquine resistance is not report

Forms & strengthsHydroxychloroquine sulfate tablets, USP are white to off white, film coated oval shaped tablets, debossed with “CE”on one side and “173”on other side.
LabelChartwell RX, LLC
Label updatedDec 12, 2025

What is Hydroxychloroquine used for?

Hydroxychloroquine sulfate tablets are indicated in adult and pediatric patients for the:

Treatment of uncomplicated malaria due to

Plasmodium falciparum, Plasmodium malariae, Plasmodium vivax,and

Plasmodium ovale.

Prophylaxis of malaria in geographic areas where chloroquine resistance is not reported.

Limitations of Use:

Hydroxychloroquine sulfate tablets are

notrecommended for:

Treatment of complicated malaria.

Treatment of malaria by chloroquine or hydroxychloroquine-resistant strains of

Plasmodiumspecies

.

Treatment of malaria acquired in geographic areas where chloroquine resistance occurs or when the

Plasmodiumspecies has not been identified.

Prophylaxis of malaria in geographic areas where chloroquine resistance occurs.

Prevention of relapses of

P. vivaxor

P. ovalebecause it is not active against the hypnozoite liver stage forms of these parasites. For radical cure of

P. vivaxand

P. ovaleinfections, concomitant therapy with an 8-aminoquinoline drug is necessary

.

For the most current information about drug resistance, refer to the latest recommendations from the Center for Disease Control and Prevention

1.

Hydroxychloroquine sulfate tablets are indicated for the treatment of acute and chronic rheumatoid arthritis in adults.

Hydroxychloroquine sulfate tablets are indicated for the treatment of systemic lupus erythematosus in adults.

Hydroxychloroquine sulfate tablets are indicated for the treatment of chronic discoid lupus erythematosus in adults.

Hydroxychloroquine dosage

Administer hydroxychloroquine sulfate orally with food or milk. Do not crush or divide the tablets.

Hydroxychloroquine sulfate is not recommended in pediatric patients less than 31 kg because the lowest available strength (200 mg) exceeds the recommended dose for these patients and it cannot be divided.

Prophylaxis

Treatment must start 2 weeks before travel to an endemic area. Advise the patient to take the prophylaxis dosage once a week, staring 2 weeks prior to travel to the endemic area, on the same day every week, continuing the same weekly dose while in the endemic area, and for 4 weeks after leaving the endemic area. The recommended prophylaxis dosage is:

Adult patients: 400 mg once a week

Pediatric patients ≥ 31 kg: 6.5 mg/kg actual body weight (up to 400 mg) once a week

Treatment of Uncomplicated Malaria

The dosages for the treatment of uncomplicated malaria are:

Adult patients: Administer 800 mg initially; subsequently administer 400 mg at 6 hours, 24 hours, and 48 hours after the initial dose (total dosage = 2000 mg).

Pediatric patients ≥ 31 kg: Administer 13 mg/kg (up to 800 mg) initially; subsequently administer 6.5 mg/kg (up to 400 mg) at 6 hours, 24 hours, and 48 hours after the initial dose (total dosage = 31 mg/kg - up to 2000 mg).

For radical cure of

P. vivax and P. ovaleinfections, concomitant therapy with an 8- aminoquinoline drug is necessary

.

The recommended dosage is:

Initial dosage: 400 mg to 600 mg daily as a single daily dose or two divided doses. The action of hydroxychloroquine is cumulative and may require weeks to months for maximum therapeutic effect. Daily doses exceeding 5 mg/kg (actual weight) of hydroxychloroquine sulfate increase the incidence of retinopathy

.

Chronic dosage: 200 mg once daily to 400 mg daily, as a single dose or two divided doses.

Corticosteroids, salicylates, and other antirheumatic agents may be used concomitantly with hydroxychloroquine sulfate.

The recommended dosage is 200 mg given once daily, or 400 mg given once daily or in two divided doses.

The recommended dosage is 200 mg given once daily, or 400 mg given once daily or in two divided doses.

How to take Hydroxychloroquine — instructions & advice from the label

Important Administration Instructions

Advise the patient to take hydroxychloroquine sulfate with food or milk and not to crush or divide the tablet.

Cardiomyopathy and Ventricular Arrhythmias

Inform the patient that serious cardiac effects, life-threatening and fatal cases have been reported with use of hydroxychloroquine sulfate Advise patients to seek medical attention immediately if

they experience any symptoms of heart rhythm changes including fast or irregular heartbeat, lightheadedness, dizziness, or syncope

.

Retinal Toxicity

Inform the patient that irreversible retinal damage has been observed in some patients with the use of hydroxychloroquine sulfate. Advise patients of the importance of the ophthalmology visits for monitoring their eyes. Instruct patients to seek medical attention promptly if they experience decreased vision or decreased dark adaptation

.

Serious Skin Reactions

Inform the patient that severe, life-threatening skin reactions have been reported with the use of hydroxychloroquine sulfate. …

Warnings & precautions

Do not take this medicine if: hydroxychloroquine sulfate tablets are contraindicated in patients with known hypersensitivity to 4- aminoquinoline compounds.

Fatal and life-threatening cases of cardiotoxicity, including cardiomyopathy, have been reported in patients treated with hydroxychloroquine sulfate. Signs and symptoms of cardiac compromise have occurred during acute and chronic hydroxychloroquine sulfate treatment. In multiple cases, endomyocardial biopsy showed association of the cardiomyopathy with phospholipidosis in the absence of inflammation, infiltration, or necrosis. Drug-induced phospholipidosis may occur in other organ systems

.

Patients may present with ventricular hypertrophy, pulmonary hypertension and conduction disorders including sick sinus syndrome. ECG findings include atrioventricular, right or left bundle branch block.

Hydroxychloroquine sulfate has a potential to prolong the QT interval. Ventricular arrhythmias (including torsades de pointes) have been reported in hydroxychloroquine sulfate -treated patients. The magnitude of QT prolongation may increase with increasing concentrations of the drug. Therefore, the recommended dose should not be exceeded

. Avoid hydroxychloroquine sulfate administration in patients with congenital or documented acquired QT prolongation and/or known risk factors for prolongation of the QT interval such as:

Cardiac disease, e.g., heart failure, myocardial infarction.

Proarrhythmic conditions, e.g., bradycardia (< 50 bpm).

History of ventricular dysrhythmias.

Uncorrected hypokalemia and/or hypomagnesemia.

Concomitant administration with QT interval prolonging agents as this may lead to an increased risk for ventricular arrhythmias

Therefore, hydroxychloroquine sulfate is not recommended in patients taking other drugs that have the potential to prolong the QT interval. Correct electrolyte imbalances prior to use. …

Hydroxychloroquine side effects

The following adverse reactions are described in greater detail in other sections:

Cardiomyopathy and Ventricular Arrhythmias

Retinal Toxicity

Serious Skin Reactions

Worsening of Psoriasis

Risks Associated with Use in Porphyria

Hematologic Toxicity

Hemolytic Anemia Associated with G6PD

Skeletal Muscle Myopathy or Neuropathy

Neuropsychiatric Reactions Including Suicidality

Hypoglycemia

Renal Toxicity

The following adverse reactions have been identified during post-approval use of 4- aminoquinoline drugs, including hydroxychloroquine sulfate. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure:

-

Blood and lymphatic system disorders: Bone marrow depression, anemia, aplastic anemia, agranulocytosis, leukopenia, thrombocytopenia

-

Cardiac disorders:Cardiomyopathy, cardiac failure, QT interval prolongation, ventricular tachycardia, torsades de pointes, atrioventricular block, bundle branch block, sick sinus syndrome, pulmonary hypertension

-

Ear and labyrinth disorders:Vertigo, tinnitus, nystagmus, sensorineural hearing loss

-

Eye disorders:Retinopathy, retinal pigmentation changes (typically bull’s eye appearance), visual field defects (paracentral scotomas), macular degeneration, corneal edema, corneal opacities, decreased dark adaptation

-

Gastrointestinal disorders:Nausea, vomiting, diarrhea, abdominal pain

-

General …

Drug interactions

Hydroxychloroquine sulfate prolongs the QT interval. There may be an increased risk of inducing ventricular arrhythmias if hydroxychloroquine sulfate is used concomitantly with other arrhythmogenic drugs. Therefore, hydroxychloroquine sulfate is not recommended in patients taking other drugs that have the potential to prolong the QT interval or are arrhythmogenic

.

Hydroxychloroquine sulfate may enhance the effects of insulin and antidiabetic drugs, and consequently increase the hypoglycemic risk. Therefore, a decrease in dosage of insulin and other antidiabetic drugs may be necessary

.

Hydroxychloroquine sulfate can lower the seizure threshold. Co-administration of hydroxychloroquine sulfate with other antimalarials known to lower the seizure threshold (e.g., mefloquine) may increase the risk of seizures.

The activity of antiepileptic drugs might be impaired if co-administered with hydroxychloroquine sulfate.

Concomitant use of hydroxychloroquine sulfate and methotrexate may increase the incidence of adverse reactions.

An increased plasma cyclosporin level was reported when cyclosporin and hydroxychloroquine sulfate were co-administered. Monitor serum cyclosporine levels closely in patients receiving combined therapy. …

About this medicine

Hydroxychloroquine Sulfate, USP is an antimalarial and antirheumatic drug, chemically described as 2-[[4-[(7-Chloro-4-quinolyl)amino]pentyl]ethylamino]ethanol sulfate (1:1) with the molecular formula C

18H

26ClN

3O.H

2SO

4. The molecular weight of Hydroxychloroquine Sulfate is 433.95. Its structural formula is:

Hydroxychloroquine Sulfate is a white or practically white, crystalline powder, freely soluble in water; practically insoluble in alcohol, chloroform, and in ether.

Hydroxychloroquine Sulfate Tablets, USP for oral administration contain 200 mg Hydroxychloroquine Sulfate (equivalent to 155 mg of Hydroxychloroquine) and the following inactive ingredients: colloidal silicon dioxide, crospovidone, hypromellose, lactose monohydrate, magnesium aluminometasilicate, magnesium stearate, polyethylene glycol, povidone, talc, and titanium dioxide.

How it works: Malaria Hydroxychloroquine is a 4-aminoquinoline antimalarial and antirheumatic agent. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 7e09aeca-0cec-4a88-9dde-a2098a08b877. Read the full official label on DailyMed.

Related medicines

Gabapentin Meloxicam Acetaminophen and Hydrocodone Duloxetine Prednisone Ibuprofen Tramadol Cyclobenzaprine